Who is Jiayao Lei?

Jiayao is keen in preventing diseases and promoting human health. With her medical background and professional training, Jiayao has prepared herself with comprehensive understanding in epidemiological study design, data management, competitive data analyses skills as well as excellent presentation skills.

She is experienced in medical epidemiology and biostatistics and currently working with cancer epidemiology research with a focus on cervical cancer prevention. Her research interest includes:

  • Prevention of cervical cancer through Pap smear screening and HPV-based screening.
  • Cervical screening among HPV-vaccinated population.
  • Cervical cancer prognosis.

Jiayao has tons of curiosity and enjoys taking new challenges. Curiosity brings her knowledge, so she is always looking for new adventure in her learning journey. She is also energetic in both work and life. Now her goal is to become a happy and fruitful PhD in her doctoral journey in Sweden.

Experience


Karolinska Institutet

PhD Student in Department of
Epidemiology and Biostatistics

Jan 2016 - Present


Epidemiology/Cancer Epidemiology The PhD project is about cervical cancer prevention with a focus on screening, including:
  • Evaluation of organized cervical screening program in Sweden. Screening effectiveness in preventing rare histological types of invasive cervical cancer.
  • Screening methods among HPV vaccinated population.
  • Cervical cancer prognosis.


World Health Organization

Intern
Jun 2015 - Aug 2015



  • Analyze AEFI reporting by country from the Joint Reporting Form in light of the new GVAP indicator.
  • Produce a list of reactions that are specific to individual vaccines and propose modalities for their field investigations as a complement to WHO’s AEFI investigation form.
  • Review and complement existing simulations of AEFI for field investigation training.
  • Review the existing AEFI rate sheets and identify the potential to apply the GRADE methodology to make them more robust.


Karolinska Institutet

Digital Ambassador
Sep 2013 - Jun 2015



In charge of digital social media of Karolinska Institute, such as blog and email administration.


Yue Bei People’s Hospital

Intern
Jun 2012 – Sep 2012



Worked in department of internal medicine, surgery, infectious disease and gynecology and obstetrics assisting basic clinical work and endowed with diagnose, treatment and other medical skills.


Sun Yat-Sen University

Research Assistant
Jun 2009 – Sep 2010



Department of Anatomy & Neurobiology, Zhongshan School of Medicine, SYSU
  • Patch clamp technique.
  • Neurotoxicology research projects.

Education

Karolinska Institutet

Karolinska Institutet is one of the world´s leading medical universities. Our mission is to contribute to the improvement of human health through research and education. Karolinska Institutet accounts for over 40 per cent of the medical academic research conducted in Sweden and offers the country´s broadest range of education in medicine and health sciences.
PhD degree: 2016 - Present
Master degree: Master of Science (MSc), Epidemiology, 2013 - 2015


 

Sun Yat-Sen University

Sun Yat-sen University, founded by Dr. Sun Yat-sen and with an educational tradition spanning over 100 years, is a preeminent research, academic and cultural center and the premier location for talent development in South China. Under the direct supervision of the Ministry of Education of the People’s Republic of China, and strongly supported by both the Ministry and Guangdong Province, Sun Yat-sen University has developed into a modern comprehensive university that enjoys a reputation as a top-tier university nationally and a renowned university internationally.
Bachelor degree: Bachelor of Medicine, 2008 - 2013

Publications

High-risk human papillomavirus status and prognosis in invasive cervical cancer: A nationwide cohort study

Lei J, Ploner A, Lagheden C, Eklund C, Kleppe SN, Andrae B, Elfström KM, Dillner J, Sparén P, Sundström K
PLoS medicine. 2018 Oct 1;15(10):e1002666.

Background
High-risk human papillomavirus (hrHPV) infection is established as the major cause of invasive cervical cancer (ICC). However, whether hrHPV status in the tumor is associated with subsequent prognosis of ICC is controversial. We aim to evaluate the association between tumor hrHPV status and ICC prognosis using national registers and comprehensive human papillomavirus (HPV) genotyping.

Methods and findings
In this nationwide population-based cohort study, we identified all ICC diagnosed in Sweden during the years 2002–2011 (4,254 confirmed cases), requested all archival formalin-fixed paraffin-embedded blocks, and performed HPV genotyping. Twenty out of 25 pathology biobanks agreed to the study, yielding a total of 2,845 confirmed cases with valid HPV results. Cases were prospectively followed up from date of cancer diagnosis to 31 December 2015, migration from Sweden, or death, whichever occurred first. The main exposure was tumor hrHPV status classified as hrHPV-positive and hrHPV-negative. The primary outcome was all-cause mortality by 31 December 2015. Five-year relative survival ratios (RSRs) were calculated, and excess hazard ratios (EHRs) with 95% confidence intervals (CIs) were estimated using Poisson regression, adjusting for education, time since cancer diagnosis, and clinical factors including age at cancer diagnosis and International Federation of Gynecology and Obstetrics (FIGO) stage. Of the 2,845 included cases, hrHPV was detected in 2,293 (80.6%), and we observed 1,131 (39.8%) deaths during an average of 6.2 years follow-up. The majority of ICC cases were diagnosed at age 30–59 years (57.5%) and classified as stage IB (40.7%). hrHPV positivity was significantly associated with screen-detected tumors, young age, high education level, and early stage at diagnosis (p < 0.001). The 5-year RSR compared to the general female population was 0.74 (95% CI 0.72–0.76) for hrHPV-positive cases and 0.54 (95% CI 0.50–0.59) for hrHPV-negative cases, yielding a crude EHR of 0.45 (95% CI 0.38–0.52) and an adjusted EHR of 0.61 (95% CI 0.52–0.71). Risk of all-cause mortality as measured by EHR was consistently and statistically significantly lower for cases with hrHPV-positive tumors for each age group above 29 years and each FIGO stage above IA. The difference in prognosis by hrHPV status was highly robust, regardless of the clinical, histological, and educational characteristics of the cases. The main limitation was that, except for education, we were not able to adjust for lifestyle factors or other unmeasured confounders.

Conclusions
In this study, women with hrHPV-positive cervical tumors had a substantially better prognosis than women with hrHPV-negative tumors. hrHPV appears to be a biomarker for better prognosis in cervical cancer independent of age, FIGO stage, and histological type, extending information from already established prognostic factors. The underlying biological mechanisms relating lack of detectable tumor hrHPV to considerably worse prognosis are not known and should be further investigated.

PMID: 30273338
DOI:  10.1371/journal.pmed.1002666
Link: https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1002666


Use of a new global indicator for vaccine safety surveillance and trends in adverse events following immunization reporting 2000–2015

Lei J, Balakrishnan MR, Gidudu JF, Zuber PLF.
Volume 36, Issue 12, 14 March 2018, Pages 1577–1582

Reporting of adverse events following immunization (AEFI) is a key component for functional vaccine safety monitoring system. The aim of our study is to document trends in the AEFI reporting ratio globally and across the six World Health Organization (WHO) regions. We describe the number of AEFI reports communicated each year through the World Health Organization/United Nations Children's Fund Joint Reporting Form on Immunization from 2000 to 2015. The AEFI reporting ratios (annual AEFI reports per 100,000 surviving infants) were calculated to identify WHO countries (n = 191 in 2000 and n = 194 by 2015) that met a minimal reporting ratio of 10, a target set by the Global Vaccine Action Plan for vaccine safety monitoring as a proxy measure for a functional AEFI reporting system. The number of countries reporting any AEFI fluctuated over time but with progress from 32 (17%) in 2000 to 124 (64%) in 2015. In 2015, the global average AEFI reporting ratio was 549 AEFI reports per 100,000 surviving infants. The number of countries with AEFI reporting ratios greater than 10 increased from 8 (4%) in 2000 to 81 (42%) in 2015. In 2015, 60% of countries in the WHO Region of the Americas reported at least 10 AEFI per 100,000 surviving infants, followed by 55% in European Region, 43% in Eastern Mediterranean Region, 33% in Western Pacific Region, 27% in South-East Asia Region and 21% in African Region. Overall, AEFI reporting has increased over the past sixteen years worldwide, but requires strengthening in a majority of low- and middle- income countries. The AEFI reporting ratio is useful for benchmarking and following trends over time; but does not provide information on the quality of the reporting system and does not guarantee capacity to detect and manage a vaccine safety problem at a national level. Additional efforts are required to ensure and improve data quality, AEFI reporting and surveillance of immunization safety in every country.

PMID: 29454518
DOI: 10.1016/j.vaccine.2018.02.012
Link: https://www.sciencedirect.com/science/article/pii/S0264410X18301865


Alumina Nanoparticles Alter Rhythmic Activities of Local Interneurons in the Antennal Lobe of Drosophila

Huang N, Yan Y, Xu Y, Jin Y, Lei J, Zou X, Ran D, Zhang H, Luan S, Gu H.
Nanotoxicology. 2013 Mar;7(2):212-20. doi: 10.3109/17435390.2011.648668. Epub 2012 Jan 20.

The special physical and chemical properties of nanomaterials open up new capabilities and functions. However, concerns have been raised about the risks produced by nanoparticles, their potential to cause undesirable effects, such as contamination of the environment and other adverse effects. In this study, we used Drosophila as a model organism to explore the effects of nano-alumina on the central nervous system. We focused on the rhythmic activities in the antennal lobe of Drosophila using patch clamps to record the electrophysiological activities. We found that 15 min after application of alumina nanoparticles, the average frequencies of spontaneous activities were significantly decreased compared with control groups (0.65 ± 0.13 Hz, 0.34 ± 0.07 Hz, *p < 0.05). These results indicated that nano-alumina might have adverse effects on the central nervous system in Drosophila.

PMID:22264077
DOI:10.3109/17435390.2011.648668
Link: https://www.ncbi.nlm.nih.gov/pubmed/22264077


Serial Paraffin Section and Hematoxylin-eosin Staining of the Amphioxus

Lei J, Xu Y, Gu H
Department of Anatomy, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, 510080, China

Objective To introduce a method for serial paraffin section and hematoxylin-eosin staining of the Amphioxus Methods Leica EG1150 Modular Tissue Embedding Center (consisting of the Leica EG1150 C Cold Plate and the Leica EG1150 H Heated Paraffin Dispensing Module),Leica VT1000S Vibrating Blade Microtome, Leica HI1210- Waterbath, Leica HI1220-Flattening Table were utilized to produce the serial paraffin sections as well as obtaining hematoxylin-eosin staining of the Amphioxus. By comparing the appearance changes and microscopic images of the Amphioxus repetitively step by step, we found out the appropriate time course of every procedure. Results We attained clear hematoxylin-eosin stained paraffin sections in that way. The sections of head, thorax, abdomen and tail were selected as the four representatives, the structures of notochord, neural tube, pharyngeal gill, ovary, myomere, intestine of the Amphioxus were clearly distinguished. Conclusion We established a successful method for serial paraffin section and hematoxylin-eosin staining of Amphioxus, and provided a new way for the further research in origin of vertebrates

Link: http://en.cnki.com.cn/Article_en/CJFDTOTAL-GDJP201005025.htm

Patents

Preparation and Applications of a Novel Kind of Biopesticide that can Kill Pest Eggs

Inventors: 张午生, 那群, 雷佳瑶
Link: https://www.google.com/patents/CN101861881B

本发明公开了一种能杀灭虫卵的生物农药及其制备方法和应用。本发明所述生物农药含有甲氨基阿维菌素、皂角素和加纳籽油。本发明通过将甲氨基阿维菌素、皂角素、加纳籽油、多元醇型非离子表面活性剂和羟甲基纤维素混合,搅拌过程中,加入水,形成均相微浑浊的乳液,得到能杀灭虫卵的生物农药。该生物农药对人居住环境中的害虫如蟑螂,白蚁,蚂蚁杀灭效果明显,杀率为95%以上,同时具有驱蚊作用。另外该生物农药除了对害虫成虫有杀伤作用,也可以杀虫卵,阻断害虫的繁殖,使得杀虫效果大为提升,克服了配方中主要活性成份甲氨基阿维菌素不能杀虫卵的局限性。同时由于群蚁、蟑螂均有相互舐理的习性,从而该生物农药能在在害虫种群中形成毒素传播。

 

Recommendations

“Lei was very active and highly motivated. Ever since her junior year, she consulted me frequently about the issues related to public health and nutrition. I also noticed that she had a clear mind of herself as well as her own ideas about career development.”

Sun Yat-Sen University

Sun Yat-Sen University

Professor and Director, Department of Nutrition

“The whole team has enjoyed Ms Lei’s hard work and good spirit. We wish her well in the pursuit of her professional training and look forward to opportunities of collaborating with her in the future.”

World Health Organization

World Health Organization

Group Lead, Vaccine Safety

Latest news

Welcome to my new webpage

Welcome to my new webpage.

See all my posts